Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Law & Regulation CDE Guideline Pharmacopoeia CMC Clinical Trial Volume-based Procurement Cancer Drug RegistrationMonthly Recap: China Pharmaceutical Regulatory Updates | April 2023 Regulatory updates in Apr. 2023: 1. China Grants Four Rx-to-OTC Switches; China Adjusts Catalogs of Anesthetics and Psychoactive Drugs; China Reveals the 8th Medical VBP’s Bidding Result...
May 15, 2023
Law & Regulation Pharmacovigilance Marketing Approval Volume-based Procurement Generic Drug Drug Registration E-commerce2022 Recap: Top 10 BaiPharm Stories on China Pharmaceutical Regulations ChemLinked BaiPharm Portal has been tracking and interpreting China’s pharmaceutical regulations during the year of 2022. Here are the top 10 stories we selected for you to grasp China’s regulatory dynamics.
Jan 13, 2023
China Suspends UCB's Antiepileptic Drug, Keppra, from Import, Sale, and Use On Aug. 24, China NMPA suspended the import, sale, and use of UCB Pharma S.A.’s Levetiracetam Concentrated Solution for Injection (Keppra), a drug for epilepsy treatment.
Aug 26, 2022
Law & Regulation Pharmacopoeia MAH Pharmacovigilance Marketing Approval Priority Review and Approval Volume-based ProcurementTop 10 BaiPharm Stories of China's Pharmaceutical Regulations | 2021 Recep ChemLinked BaiPharm Portal has been delivering and decoding China's pharmaceutical regulations to help international drug makers access the Chinese market. Here are the 10 regulatory topics that our readers are most concerned about in 2021.
Jan 07, 2022
- [Updated] China Issues the 2020 Edition of Chinese Pharmacopoeia
- Monthly Report: New Drug Approvals in China | March 2023
- What's New About China's 8th Volume-based Procurement (VBP) of Drugs
- Monthly Recap: China Pharmaceutical Regulatory Updates | March 2023
- For Injectable Complex Generics, China Has Special CMC Requirements